The FDA must stop approving new opioid drugs now and improve its flawed regulatory processes, the chairman of an agency drug advisory committee says.
The agency is green-lighting painkillers without enough evidence that they’re safe or in some cases even necessary, the committee’s chairman, Raeford Brown, said in an interview. And despite being handed a list of recommendations from the National Academies of Sciences, Engineering, and Medicine in 2017 on how to improve opioid approval regulations, “there’s no interest in implementing them,” Brown said.
The FDA didn’t respond to questions or a request for comment March 21.
The National Academies’...